Hepion Pharmaceuticals (Hepion Pharmaceuticals) Cash-to-Debt : 70.75 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hepion Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 70.75.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Hepion Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Hepion Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

HEPA' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.97 Med: 514.28 Max: No Debt
Current: 70.75

During the past 11 years, Hepion Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 1.97. And the median was 514.28.

HEPA's Cash-to-Debt is ranked better than
76.32% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs HEPA: 70.75

Hepion Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Hepion Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hepion Pharmaceuticals Cash-to-Debt Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

17.23

54.16

288.17

947.94

70.75

Hepion Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															947.94	No Debt	No Debt	80.02	70.75

Competitive Comparison of Hepion Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Hepion Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hepion Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's Cash-to-Debt falls into.

Hepion Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hepion Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	14.786	/	(0.116	+	0.093)
	=	70.75

Hepion Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	14.786	/	(0.116	+	0.093)
	=	70.75

Hepion Pharmaceuticals (NAS:HEPA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hepion Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Executives

Peter Wijngaard	director	8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster	officer: Chief Scientific Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan	officer: Chief Financial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: CEO and President
Donald E Garlikov	10 percent owner	41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson	director
Thomas Phd Adams	director
Gabriel Cerrone	10 percent owner	VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai	officer: Chief Medical Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein	director, officer: Chief Executive Officer	1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa	director	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung	officer: Chief Financial Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170